PRP vs GFC vs Mesotherapy for Hair Loss: Evidence and Uncertainty

Evidence summary: PRP, growth-factor concentrate labels and mesotherapy are not interchangeable terms. Published studies differ in the material prepared or injected, the preparation method, additional procedures, treatment schedule, diagnosis, follow-up and outcome measured.^[1][3][4][6] The current literature does not support one universal choice for every person with hair loss. Evidence signals are diagnosis-specific and should not be extrapolated from one cause of hair loss to another.

This guide explains what the labels can mean, what selected reviews and trials report, and which uncertainties should be checked before considering an intervention. It does not diagnose hair loss, determine suitability, prescribe treatment or predict an individual result.

What is PRP?

Platelet-rich plasma (PRP) is prepared from a person’s own blood. The published literature includes different preparation systems, platelet concentrations, activation methods, injection schedules and co-interventions. A systematic review covering androgenetic alopecia and alopecia areata found heterogeneity in PRP types and administration schedules, and it rated the hair-density evidence against saline as low quality because of inconsistency and risk of bias.^[1]

A separate review of nine randomized trials in androgenetic alopecia reported a hair-density difference at selected follow-up points, while hair count and hair diameter were not significantly different from placebo. These outcome-specific findings should not be converted into a guaranteed response, a fixed timetable or a standard protocol.^[2]

What do GFC, PRGF and CGF mean?

Growth-factor concentrate (GFC), plasma rich in growth factors (PRGF) and concentrated growth factor (CGF) are labels used for blood-derived preparations or processing approaches across parts of the published literature. The label alone does not establish the device, processing steps, final composition or injected dose. Two products or protocols with similar names should not be assumed to be equivalent without those details.^[4]

A recent systematic review in androgenetic alopecia grouped PRP, PRGF and other growth-factor concentrates, but reported high risk of bias in randomized studies, serious-to-critical bias in non-randomized studies, substantial heterogeneity and non-standardized protocols. Its findings were described as hypothesis-generating. One small split-scalp study in androgenetic alopecia compared PRP plus microneedling with PRP plus microneedling plus CGF; that design cannot isolate CGF as a standalone treatment or establish that all growth-factor concentrate labels refer to the same intervention.^[4][5]

What is mesotherapy?

Mesotherapy is an intradermal injection technique rather than one single medicine. A systematic review identified studies using six classes of agents and combinations, including medicines, growth factors or autologous preparations, botulinum toxin, cell-based preparations and multicomponent solutions. The review found no standardized regimen, noted reported adverse effects and called for larger controlled trials.^[6]

For that reason, “mesotherapy” is incomplete as a treatment description unless the injected material, concentration, preparation, schedule and evidence for the person’s diagnosis are specified. Adverse effects and contraindications depend on the exact injectate, preparation and any co-intervention; a technique or concentrate label alone does not define a safety profile.^[6]

How does the evidence compare?

Label	What must be identified	Evidence signal in the selected literature	Important limitation
PRP	Preparation system, composition, activation, schedule and co-interventions	Studies in selected diagnoses, including androgenetic alopecia and alopecia areata, report changes in selected hair measures [1][2]	Protocols and outcomes vary; some pooled evidence is low quality or outcome-specific
GFC, PRGF or CGF	Exact preparation, processing steps, composition and whether another procedure is combined	Early studies in androgenetic alopecia report changes in selected measures [4][5]	Labels and protocols are not standardized; bias and heterogeneity limit comparative conclusions
Mesotherapy	Exact injected agent, concentration, schedule and evidence for the diagnosis	Studies cover multiple agents and combinations [6]	It is a delivery technique, not a single intervention; regimens are not standardized

The table compares evidence categories, not clinic products. It does not rank treatments or show that one protocol is suitable for a particular person.

Why can two studies reach different conclusions?

• Different diagnoses: androgenetic alopecia, alopecia areata and other causes of hair loss are not the same condition.
• Different preparations: centrifugation, concentration, activation and final composition can differ.
• Different combinations: needling, medicines or other procedures may be used alongside an injection.
• Different outcomes: density, count, shaft diameter, photographs, shedding and patient-reported measures answer different questions.
• Different follow-up: a short observation period cannot establish long-term durability.
• Different study quality: small samples, weak controls, inconsistent reporting and risk of bias can change confidence in a result.

Questions to ask before considering an injection procedure

1. What diagnosis is being treated, and how was it established?
2. What exactly will be prepared or injected?
3. Which preparation system, concentration and processing steps will be used?
4. Will needling, medicines or another procedure be combined with it?
5. Which study population and outcome measure are most relevant to this proposed protocol?
6. What is uncertain about the expected response and its durability?
7. What adverse effects, contraindications and alternatives should be discussed?
8. How will baseline findings, follow-up and any adverse event be documented?

An individual assessment may identify a different diagnosis, a reason to defer an intervention or a non-procedural alternative. A comparison page cannot make that decision.

What this guide cannot tell you

The cited studies do not verify a clinic’s product, device, preparation protocol, clinician credentials, case volume, patient result or service claim. They also do not prove that similarly named preparations are equivalent. Those facts require separate, direct verification.

How this page was prepared

Version 1.0. Source search completed 4 August 2026. The page uses selected PubMed-indexed systematic reviews and controlled studies to distinguish evidence signals from study limitations. Sources were selected for direct relevance to PRP, growth-factor concentrate terminology or mesotherapy in hair loss. This is a focused evidence guide, not a complete systematic review. The general approach to source hierarchy, claim boundaries and visible uncertainty is described in How We Intend to Read and Explain Clinical Evidence.

Medical references

• Systematic review and meta-analysis of PRP for alopecia (27 controlled trials). PubMed PMID 34967722.
• Systematic review and meta-analysis of randomized PRP trials in androgenetic alopecia. PubMed PMID 37533146.
• Randomized pilot study of PRP growth-factor concentrations and response variability. PubMed PMID 31984508.
• Systematic review and meta-analysis of growth-factor injections in androgenetic alopecia. PubMed PMID 42126441.
• Split-scalp study of PRP and a PRP-plus-CGF combination. PubMed PMID 41971493.
• Systematic review of mesotherapy for hair loss. PubMed PMID 37558233.

Medical scope: This page provides general educational information. It does not replace diagnosis, informed consent or advice from an appropriately qualified clinician who has assessed the individual.